Sharechat Logo

Comvita ordered to pay GBP400,000 in costs

Monday 7th February 2011

Text too small?

Natural health products company Comvita says it will appeal after a British court ordered it to pay costs of up to 400,000 pounds (NZ$837,000) after the company lost a patent infringement case.

Comvita said today it would apply to the British Court of Appeal, after legal advice confirmed the company's view that the original court ruling was flawed on several grounds to Comvita's disadvantage.

In December Comvita reported the Patents County Court in Britain had ruled against Comvita's claim of patent infringement by company Brightwake. The judge had ruled Comvita's patent invalid.

At the time, Comvita described the ruling as "extremely disappointing and unexpected".

Today Comvita said it was to make an interim costs payment of 287,000 pounds to Brightwake by the end of February, with details of the balance to be decided at a future court hearing.

Comvita would take a provision of costs for the full amount this financial year.

The cost to Comvita of its appeal was expected to be less than 100,000 pounds, the company said.

A stay on revocation of Comvita's patent had been granted by the British courts until an appeal, if granted, was heard.

Also today, Comvita said its global licensee for Medihoney specialist wound care products, Derma Sciences Inc, had announced positive results of a phase 2 clinical trial for new wound healing drug DSC127.

Comvita had a 13% ownership - 11.6% fully diluted for all warrants and options on issue - of Derma Sciences, a Nasdaq public listed company.

Derma Sciences' share price had more than doubled in the lead up to and since the announcement, and that had a material impact on the value of Comvita's strategic shareholding in Derma Sciences, Comvita said.

 

NZPA



  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

TruScreen Group Limited (NZX: TRU) Clinical Trial Results Highlight Efficacy of TRU Technology
20th October 2021 Morning Report
Freightways Limited (NZX: FRE) Acquisition of ProducePronto
19th October 2021 Morning Report
PGG Wrightson Limited (NZX: PGW) Guidance Update
Vital Limited (NZX: VTL) Provides Update on PSN LMR
18th October 2021 Morning Report
T&G Global Limited (NZX: TGG) FY21 Earnings Guidance Update
Arvida Group Limited (NZX: ARV) Successful Completion of $155m Placement
FreshLeaf: Cannabis on course to be 'medicine of the masses'